Sonas Pharma announced that the SNS-101 series is a deliberately engineered molecule aimed at a specific problem in paediatric epilepsy.
Public source
Publisher name
Public post
Someone asked me last week about how we've changed the molecules and what actually happens to the molecules inside the body — fair question, and I wanted to try and answ…
Company
Sonas Pharma
Innovative ECS medicines for the future.
- Industry
- Biotechnology Research
- Location
- Belfast, GB
- Company size
- 2–10 employees
About Sonas Pharma
Developing innovative ECS medicines to treat epilepsy and obesity.
See moreLatest activity
Latest activity from Sonas Pharma
3 signals
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
EpilepsyGTx
EpilepsyGTx announced that EPY201, its lead gene therapy candidate, has the potential to transform outcomes for 10 million people living with focal refractory epilepsy globally.
Research & Knowledge
Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc. Chief Medical Officer Chris Kenney, MD, MBA, FAAN addresses why new MOAs are important in the epilepsy treatment landscape.
Research & Knowledge
Biogen
Biogen shared the latest data from its investigational study for Dravet syndrome exploring the disease's underlying genetic cause at the EEC2026 medical symposium.
Research & Knowledge
Yamo Pharmaceuticals
Yamo Pharmaceuticals announced that L1-79, the only drug in the world under development to treat the core symptoms of autism, is moving into phase 3.
Research & Knowledge
Encoded Therapeutics Inc.